PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX - CISMeF
PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenXLOINC code
Preferred Label : PhenX - human papillomavirus vaccine use protocol 100802:-:Pt: Patient:-:PhenX;
LOINC status : ACTIVE;
LOINC long common name : PhenX - human papillomavirus vaccine use protocol 100802;
LOINC short name : PhenX - HPV vaccine use protocol;
LOINC description : The interviewer asks the individual whether s/he ever received a human papillomavirus
(HPV) vaccination. If the response is yes, the interviewer asks about number of shots
received. If the participant answers yes to question 1, the interviewer should complete
the rest of the protocol. If the participant answers no, then the protocol is deemed
complete. The PhenX Working Group notes that GARDASIL is also known internationally
as Silgard. European Medicines Agency. (2009, September 25). Silgard European Public
Assessment Report. Waknine, Y. (2006, October 2). International approvals: Singulair
and Gardasil/Silgard. Medscape Today. Note: GARDASIL by Merck & Co. is approved by
the U.S. Food and Drug Administration (FDA) for use in females ages 9-26 and males
ages 9-26. Note: CERVARIX is manufactured by GlaxoSmithKline Biologicals and approved
by the FDA for use in females ages 10-25.;